Skip to main content

Drug Interactions between delavirdine and nevirapine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nevirapine delavirdine

Applies to: nevirapine and delavirdine

MONITOR: The coadministration of delavirdine in combination with other non-nucleoside reverse transcriptase inhibitors (NNRTIs) like efavirenz or nevirapine has not been studied. However, since all three drugs are metabolized by the CYP450 3A4 isoenzyme, pharmacokinetic interactions may theoretically occur. Delavirdine is a potent inhibitor of CYP450 3A4 and may increase the plasma concentrations of both efavirenz and nevirapine. Nevirapine, on the other hand, is an inducer of the isoenzyme and may decrease the plasma concentrations of delavirdine. Efavirenz may have variable effects on delavirdine because it can induce as well as competitively inhibit CYP450 3A4 metabolism.

MANAGEMENT: Clinical monitoring for altered effects of both delavirdine and the other NNRTI may be appropriate following addition or withdrawal of one or the other drug.

References (4)
  1. (2001) "Product Information. Viramune (nevirapine)." Boehringer-Ingelheim
  2. (2001) "Product Information. Rescriptor (delavirdine)." Pharmacia and Upjohn
  3. (2001) "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals
  4. Developed by the panel of Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) (2004) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://AIDSinfo.nih.gov

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Nnrtis

Therapeutic duplication

The recommended maximum number of medicines in the 'NNRTIs' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'NNRTIs' category:

  • delavirdine
  • nevirapine

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.